Alnylam Pharmaceuticals Inc (ALNY) delivered better-than-expected financial results for the third quarter of fiscal 2025. The company's earnings per share (EPS) reached $2.11, significantly surpassing Wall Street's consensus estimate of $0.76 by $1.35. Additionally, revenue for the quarter totaled $1.2 billion, exceeding expectations of $1.0 billion.
This update provides insight into Alnylam's operational performance and financial health, suggesting stronger-than-anticipated business fundamentals. The company, headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, and Leqvio, the latter being developed in partnership with Novartis AG.
Alnylam Pharmaceuticals will host an earnings conference call to discuss these results and provide further commentary on its business performance. Investors are encouraged to review the full earnings release and listen to management's insights for a complete context of the quarter's performance and future outlook.
With a market capitalization of approximately $58.19 billion, Alnylam continues to be a significant player in the biotechnology industry, employing around 2,230 individuals. Looking ahead, the company is set to report its next earnings on July 28, 2026, with an EPS estimate of 0.8269 and revenue expectations of $1.2 billion.